Benzinga editor, Tony Noto, interviewed Lance Alstodt, BioRestorative’s (NASDAQ:BRTX) Chief Executive Officer, about the company’s two core clinical development programs (BRTX-100 targeting disc/spine disease and ThermoStem targeting obesity and metabolic disorders), as well its recently launched commercial BioCosmeceutical products business.
The interview can be accessed here.
